[Use of conjugated allergen-polymer vaccines (pollen allergens of new generation) for allergen-specific immunotherapy].

Aim: To assess effectiveness of new pollen allergotropins for allergen-specific immunotherapy (ASI).
Material and Methods: The allergotropins were produced basing on conjugation of pollen allergoids (timothy, birch, mugwort pollen) and polyelectrolite (polyoxidonium) with immunomodulating properties. Pollen allergotropins (timpol, berpol) were designed to treat pollenosis caused by sensitization to timothy and birch pollen. Pollen allergotropins were studied in ASI given to 140 patients with pollenosis and 10 patients with bronchial asthma.
Results: In the group of pollenosis patients with hypersensitivity to birch pollen the response to berpol was excellent in 55% patients (the disease symptoms disappeared, antihistamine drugs intake was stopped), good--in 33%, satisfactory--in 12%. Timpol produced a marked response in all the patients treated for hypersensitivity to timothy pollen.
Conclusion: Pollen allergotropins have a high therapeutic effect under low risk of provoking reactions of anaphylactic type in patients on ASI.